DMK Pharmaceuticals Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMKPQ research report →
Companywww.dmkpharmaceuticals.com
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
- CEO
- Eddie Wabern Glover
- IPO
- 1995
- Employees
- 11
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $1.01K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -60.93%
- Op Margin
- -526.88%
- Net Margin
- -556.72%
- ROE
- -209.88%
- ROIC
- 20462.31%
Growth & Income
- Revenue
- $4.76M · 115.34%
- Net Income
- $-26,478,273 · 42.22%
- EPS
- $-12.37 · 44.40%
- Op Income
- $-25,058,966
- FCF YoY
- 31.86%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.79
- Avg Volume
- 3.06K
Get TickerSpark's AI analysis on DMKPQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DMKPQ Coverage
We haven't published any research on DMKPQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DMKPQ Report →